Clinical Trial Update: Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating first-line paclitaxel (Taxol) plus carboplatin for epithelial ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Taxol (paclitaxel)

Snippet

Sponsor: North Eastern German Society of Gynaecological Oncology | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED